Novo Nordisk and Glooko announced Monday a non-exclusive collaboration to deliver jointly-developed and branded digital health solutions for people with diabetes, using "Novo Nordisk's deep knowledge of diabetes with Glooko's digital platform and data analytics expertise." Financial terms of the deal were not disclosed.
Glooko CEO Rick Altinger remarked that the partnership "aims to empower tens of millions of patients with digital tools to make diabetes management easier" by "delivering jointly-branded capabilities that will enhance the collaboration between patient and healthcare professionals."
Under the deal, Novo Nordisk and Glooko said they will build on the latter's mobile and web platforms to deliver "personalised, digital services to support people…in areas including treatment adherence and blood glucose management." The companies added that the joint offerings will help healthcare professionals "engage and manage patients with the aid of population-wide data reporting." Meanwhile, Novo Nordisk will integrate these offerings within its Digital Health Platform developed  with IBM Watson Health "to generate increasingly valuable insights into diabetes management and treatment outcomes."
Christian Kanstrup, Novo Nordisk's senior vice president of strategy, access and marketing, commented that "we are excited to partner with Glooko and to take another step towards delivering digital health offerings that help people with diabetes to improve their blood glucose control."